

Certificate of Analysis for MRA-326

Plasmodium falciparum, Strain ITG-2G2

Catalog No. MRA-326

Product Description: Plasmodium falciparum (P. falciparum), strain ITG-2G2 was isolated in

Brazil.

Lot¹: 63937216 Manufacturing Date: 22DEC2015

TEST	SPECIFICATIONS	RESULTS		
Identification by Giemsa Stain Microscopy ²	Blood-stage parasites present	Blood-stage parasites present		
Antimalarial Susceptibility Profile (in vitro) Half-maximal Inhibitory Concentration (IC50) by SYBR green I® drug sensitivity assay³ Chloroquine Artemisinin Quinine Cycloguanil	Report results Report results Report results Report results	45.0 ± 2.1 nM 13.1 ± 0.9 nM 339.4 ± 23.5 nM 876.7 ± 43.5 nM		
Pyrimethamine Sulfadoxine	Report results Report results	24.4 ± 1.7 nM 514600 ± 83303 nM Consistent with <i>P. falciparum</i> (Figure 1) ~ 800 base pair amplicon		
Genotypic Analysis Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 800 base pairs) MSP2 PCR amplicon analysis ⁴	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon			
Level of Parasitemia Pre-freeze ⁵ Post-freeze ⁶	Report results > 1%	3.44% 1.78%		
Viability (post-freeze) ⁷	Growth in infected red blood cells	Growth in infected red blood cells		
Sterility (21-day incubation) Harpo's HTYE broth ⁸ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth	No growth		
Mycoplasma Contamination DNA Detection by PCR	None detected	None detected		

¹MRA-326 was produced by cultivation of MRA-326 lot 2319626 in fresh human erythrocytes in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 μg/mL hypoxanthine and 2.5 μg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 5 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

³A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In Methods in Malaria Research Sixth Edition. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx].

⁴Primer sequences and conditions for PCR are available upon request.

⁵Pre-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.

⁶Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.



Certificate of Analysis for MRA-326

Viability was confirmed by examination of infected erythrocytes for parasitemia at 5 days post infection.
 Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-326 MSP2 Sequence

ATTTATTTAT	TGAAGCAATA	TTACTAGAGT	TATTTAAGAG	GGATGTTGCT	GCTCCACAGT	TTTCTTTGTT	ACCATCGGTA
CATTCTTTTT	GACTATCAGA	AGTATTTTGT	GGATGATTAT	TTCTAGAACC	ATGCATATGT	CCATGTTGTC	CTGTACCTTT
ATTCTCTGGT	GCAGATTGTA	ATTCGGGGGA	TTCAGTTTGT	TCGGCTGTTG	GAGCAGAATT	TTCAGCTTGT	TCAGGTTGTG
CAGTAGGACT	TTTAGTGTCT	GCATCTTGAG	TGGGTGGAAC	ATTTGATTTA	GTTTGAGAGT	CTTGTTGAAC	ATTTGAGTTA
TTTTGAGTTT	CTTTATTTGC	TTGATTTGTT	TCGGCATTAT	TATGATTTGG	ATTTTCTGAA	GAGGTACTGG	TAGATGCTTC
TGCATCATTA	GTAGTTGTGG	TAGTTGTGGT	AGTAGCGGGA	GTACTTGGAC	TTCTCTCAGC	ATCTGCACCA	GGATTAGCAC
CATTACCATC	ACCAGAACCA	GCACTACCAC	CAGCACTACC	ACCAGCACTA	CCACCAGCAC	TACCACCAGC	ACTACCACCA
GCACTACCAC	CAGCACTACC	ACCAGCACTA	CCACCAGCAC	TACCACCAGC	ACTACCACCA	GCACTACCAC	CAGCACTACC
ACCAGCACTA	CCACTAGCAC	CAGTAGGAGG	ATTACTTTCT	GTCATACTTC	TCCTTATACT	CATATTATAA	GCATTGTTTA
TGAATGTGTT	GCTATATTTA	CTTTCATTTT	TAATATTAAA	GGTAACAAAA	ATAAAGAAAT	TTATAATAGA	CAATGTTTTA
AT							

Date: 10 MAY 2016 Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use. Support Provided by NIAID

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

MRA-326_63937216_10MAY2016